Genmab AS

Genmab AS Years Dividend Increased

Years of Consecutive Dividend Increases of Genmab AS (GMAB) as of Nov 5, 2026.

Years Dividend Increased

-

Last updated:

Years of Consecutive Dividend Increases of Genmab AS is 2026 - . Years of Consecutive Dividend Increases of Genmab AS was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Genmab AS Stock analysis

What does Genmab AS do? Genmab AS is a biotechnology company based in Copenhagen, Denmark, operating in the Health Care sector. It develops and markets antibody-based therapies for cancer and other diseases, including EPKINLY, TEPKINLY, and Tivdak for various lymphomas and cervical cancer. The company also advances several product candidates in clinical development, such as Epcoritamab for lymphomas and GEN1059 for solid tumors, alongside established treatments like DARZALEX and TECVAYLI for multiple myeloma and other conditions. Genmab AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab AS stock

On Eulerpool you can find the complete historical development of Years of Consecutive Dividend Increases Genmab AS since 2006 – with annual values, charts, and detailed analysis.

This measures how many consecutive years the dividend has been raised. Companies with 25+ years are considered Dividend Aristocrats.

Years of Consecutive Dividend Increases's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Years of Consecutive Dividend Increases's Genmab AS historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Dividend — Genmab AS

DividendDividend YieldDividend per ShareYears Dividend PaidYears Dividend Not DecreasedYears Dividend IncreasedDividend Coverage

All Key Metrics — Genmab AS